Pandemic flu in russia: Special features of a clinical course and the absence of early etiotropic therapy as a risk factor of severe forms of the disease

Terapevticheskii Arkhiv

Volumn 83, Issue 9, 2011, Pages 48-53

  Kolobukhina, L V ^a   Merkulova, L N ^a   Schelkanov, M Yu ^a   Burtseva, E I ^a   Lavrischeva, V V ^a   Samokhvalov, E I ^a   Alkhovsky, S V ^a   Prilipov, A G ^a   Proshina, E S ^a   Avdeev, S N ^c   Sutochnikova, O A ^c   Bazarova, M V ^b   Kelti, E I ^b   Tserukalova, N D ^b   Blank, I A ^b   Shestakova, O M ^b   Kolivashko, O N ^b   Arseneva, T V ^b   Ambrosi, O E ^b   Shuldyakov, A A ^d   Popov, A F ^c   Simakova, A I ^e   Malyshev, N A ^b   Chuchalin, A G ^c   Lvov, D K ^a   more..

^a D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^b Infectious Hospital N 1   (Russian Federation)

^c Research Institute of Pulmonology   (Russian Federation)

^d SARATOV STATE MEDICAL UNIVERSITY   (Russian Federation)

^e PACIFIC STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Flu; Ingavirin; Oseltamivir; Pandemia; Treatment efficacy

Indexed keywords

AMIDE; ANTIVIRUS AGENT; DICARBOXYLIC ACID; IMIDAZOLE DERIVATIVE; OSELTAMIVIR; PENTANEDIOIC ACID IMIDAZOLYL ETHANAMIDE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PANDEMIC; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RUSSIAN FEDERATION; TIME; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; AMIDES; ANTIVIRAL AGENTS; DICARBOXYLIC ACIDS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; PANDEMICS; RISK FACTORS; RUSSIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80555145839     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Update: Influenza activity -United States, august 30, 2009January 9, 2010. Morbid. Mortal. Wkly Rep. 2010; 59 (02): 38-43.
2. CDC: www.cdc.gov.
3. Xu L., Bao L., Lv Q. et al. A single-amino-acid substitution in the HA protein changes the replication and pathogenicity of the 2009 pandemic A(HlNl) influenza viruses in vitro and in vivo. Virol. J. 2010; 7 (1): 325.
4. Ye J., Sorrell E. M., Cai Y. et al. Variations in the hemagglutinin of the 2009 HlNl pandemic virus: potential for strains with altered virulence phenotype? PLoS Pathog. 2010; 6 (10): el001145.
5. Gambaryan A. S., Tuzikov A. B., Pazynina G. V. et al. H5N1 chicken influenza viruses display a high binding affinity for the
6. Neu5Acα2-3Galßl-4(6-HS03)GlcNAc receptor. Virology 2004; 326 (2): 310-316.
7. Yamnikova S. S., Gambaryan A. S., Tuzikov A. B. et al. Differences between HA receptor-binding sites of avian influenza viruses isolated from Laridae and Anatidae. Avian Dis. 2003; 47 (3, Suppl.): 1164-1168. (Pubitemid 37143907)
8. Nicholls J. M., Bourne A. J., Chen H. et al. Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respir. Res. 2007; 8 (73): 1-10.
9. Gao R., Dong L., Dong J. et al. A systematic molecular pathology study of a laboratory confirmed H5N1 human case. PLoS One 2010; 5 (10):e13315.
10. Piwpankaew Y., Monteerarat Y., Suptawiwat O. et al. Distribution of viral RNA. sialic acid receptor, and pathology in H5N1 avian influenza patients. Acta Pathol. Microbiol. Immunol. Scand. 2010; 118 (11): 895-902.
11. Glaser L., Stevens J., Zamarin D. et al. A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J. Virol. 2005; 79 (17): 11533-
12. Stevens J., Blixt O., Glaser L. et al. Glycan microarray analysis of the hemagglutinins from modem and pandemic influenza viruses reveals different receptor specificities. J. MoI. Biol. 2006; 355 (5): 1143-1155. (Pubitemid 43012153)
13. Lederberg J. Infectious diseases as an evolutionary paradigm. Emerg. Infect. Dis. 1997; 3 (4): 1-9.
14. Kilander A., Rykkvin R., Dudman S. G., Hungnes O. Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A (H1N1) virus and severe clinical outcome, Norway 2009-2010. Euro Survell. 2010; 15 (9): 19498.
15. WHO Report. Preliminary review of D222G amino acid substitution in haemagglutinin of pandemic influenza A(H1N1) 2009 viruses. 28 December 2009. http://www.who.int/csr/resources/publications/swineflu/h1n1-d222g/en/index.html.
16. Bartlett J. G. 2009 H1N1 influenza -just the facts: clinical features and epidemiology, http://www.medscape.com/resource/influenza. Posted: 09/25/2009.
17. Chang T. T., Sun M. F., Chen H. Y. et al. Screening from the world's largest TCM database against H1N1 virus. J. Biomol. Struct. Dyn. 2011; 28 (5): 773-786.
18. Yates L., Pierce M., Stephens S. et al. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. Hlth Technol. Assess. 2010; 14 (34): 109-182.
19. WHO. Guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses revised february 2010 Part I, II. Recommendations. Geneva, 2010.
20. Shope R. E. Swine influenza: III. Filtration experiments and etiology. J. Exp. Med. 1931; 54: 373-385.